IXICO

London, United Kingdom Founded: 2004 • Age: 22 yrs
AI-based medical image management and analysis solutions for healthcare organizations
Annual revenue $8.8M Latest available
Total funding - 6 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products 3 Services tracked
Competitors 9 Brand Intelligence

About IXICO

IXICO is a company based in London (United Kingdom) founded in 2004. IXICO has completed 1 acquisition, including Optimal Medicine. IXICO offers products and services including IXICO Platform, Imaging Biomarkers, and Trial Management. IXICO operates in a competitive market with competitors including Perspectum, Qure.ai, Zebra Medical Vision, Deeptek and Subtle Medical, among others.

  • Headquarter London, United Kingdom
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Ixico Plc
Operational Areas
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Healthcare → Health Technology & Digital Health Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $8.78 M (USD)
    13.32
    as on Sep 30, 2025
  • Net Profit
    -$2.22 M (USD)
    17.49
    as on Sep 30, 2025
  • EBITDA
    -$2.85 M (USD)
    11.96
    as on Sep 30, 2025
  • Latest Funding Round
    $5.2 M (USD), Post-IPO

    Nov 06, 2024

  • Investors
    Gov.uk

    & 2 more

  • Employee Count
    Not available
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of IXICO

IXICO is a publicly listed company on the LSE with ticker symbol IXI in UK, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: LSE · Ticker: IXI · Sector: Commercial services · UK

Products & Services of IXICO

IXICO offers a comprehensive portfolio of products and services, including IXICO Platform, Imaging Biomarkers, and Trial Management.

Product name locked
Category locked
Primary

AI-driven tool for neuroimaging and clinical trial data analysis

Product name locked
Category locked
Locked

Provides radiological reads and MRI analysis for disease tracking

Product name locked
Category locked
Locked

Manages global clinical trials data for neurological research

People of IXICO

Headcount 50-200
Employee Profiles 34
Board Members and Advisors 4
Employee Profiles
People
Jade Hue
Clinical Project Manager
People
Nicoletta Vitale
Senior Project Start-Up Manager
People
Serena P-Ramji
Senior Project Start-up Manager
People
Veena Supramaniam
Head Of Project Management

Unlock access to complete

Board Members and Advisors
people
Mark Warne
Non-Executive Director & Senior Independent Director
people
John Bradshaw
Non-Executive Director
people
Kate Rogers
Non-Executive Director
people
Charles Spicer
Non-Executive Chairman

Unlock access to complete

Funding Insights of IXICO

Investors in IXICO

IXICO has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Gov.uk, Cavendish Corporate Finance and SBRI Healthcare.

All
Institutional
Investor Description Founded Year Domain Location
Delivers business and technological solutions to identify and address healthcare challenges.
Locked Locked Locked
Online government services and information are provided to users.
Locked Locked Locked
Mid-market investment banking services are provided to clients.
Locked Locked Locked
Premium access

Investor details for IXICO

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by IXICO

IXICO has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Optimal Medicine.

Investments
Premium access

Investment portfolio details for IXICO

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
CDS platform for ADHD assessment and treatment is provided.
Locked Locked 2012 Locked
Premium access

Complete acquisition details for IXICO

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - IXICO

Premium access

Detailed financials for IXICO

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ixico Comparisons

IXICO Primary company
Description
AI-based medical image management and analysis solutions for...
Location
London, United Kingdom
Founded Year
2004
Annual Revenue
$8.78 M (USD)
Net Profit
-$2.22 M (USD)
EBITDA
-$2.85 M (USD)
Employees
Not available
Premium access

Peer comparison for IXICO

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of IXICO

IXICO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Perspectum, Qure.ai, Zebra Medical Vision, Deeptek and Subtle Medical, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Precision medicine software for liver disease diagnosis is offered.
Locked Locked Locked
AI-powered solutions for medical imaging diagnostics
Locked Locked Locked
Provider of AI and SaaS-based medical image based decision support tools
Locked Locked Locked
AI-augmented diagnostic tools for radiology imaging are developed.
Locked Locked Locked
AI-driven solutions for medical diagnostic imaging are developed.
Premium access

Detailed competitors of IXICO

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ixico

Premium access

Complete news archive for IXICO

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about IXICO

IXICO was founded in 2004 and raised its 1st funding round 8 years after it was founded.

IXICO is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Annual revenue of IXICO is $8.78M as on Sep 30, 2025.

AI-based medical image management and analysis solutions for healthcare organizations. It provides clinical trial services for drug development in the field of neurodegeneration. One of their product ASSESSSA assists in decision support to healthcare professionals. The company has two proprietary technology, TrialWire, and TrialTracker, and these are used to collect Alzheimers patients data across the world. Also, they have wearable sensors that allow the measurement of parameters, such as sleep, and activity.

IXICO's top competitors include Perspectum, Qure.ai and Deeptek.

IXICO offers IXICO Platform, Imaging Biomarkers, and Trial Management.

Yes, IXICO is publicly traded on LSE under the ticker symbol IXI.

IXICO has made 1 acquisition, including Optimal Medicine.

IXICO has 3 investors. Key investors include Gov.uk, Cavendish Corporate Finance, and SBRI Healthcare.

The ticker symbol of IXICO is IXI on LSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available